Overview:
Care of patients with chronic lymphocytic leukemia (CLL), the most common hematologic leukemia among adults worldwide, has rapidly evolved away from chemoimmunotherapy to therapy that disrupts B-cell receptor signaling including inhibitors of Bruton's tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2). Clinical trials continue to optimize these treatments in order to maximize efficacy, minimize toxicity, and address areas of unmet need.
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes is an accredited live virtual webcast designed to rapidly disseminate new clinically relevant data with appropriate context. Faculty will focus on best practices and active areas of debate across the disease continuum.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Assess the role of risk stratification, MRD assessment and resistance mechanisms in treatment selection and personalization for patients with CLL across multiple therapy lines
- Analyze trial results from studies that evaluated BCL2-inhibitor based strategies in patients with CLL across all therapy lines
- Devise effective strategies to monitor and mitigate treatment-related toxicities in patients with CLL
